Document is current
Any future updates will be listed below
-
Authors
Karg, M. V.
Bosch, A.
Kannenkeril, D.
Striepe, K.
Ott, C.
Schneider, M. P.
Boemke-Zelch, F.
Linz, P.
Nagel, A. M.
Titze, J.
Uder, M.
Schmieder, R. E. https://orcid.org/0000-0003-2356-5883
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02383238 at ClinicalTrials.govDocuments that mention this clinical trial
SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial
https://doi.org/10.1186/s12933-017-0654-z
Early vascular parameters in the micro- and macrocirculation in type 2 diabetes
https://doi.org/10.1186/s12933-018-0770-4
A randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation
https://doi.org/10.1186/s12933-017-0510-1
-
Funding
Funding for this research was provided by:
Bristol-Myers Squibb
AstraZeneca Canada
- License Information
-
More Information
Article History
Received: 29 September 2017
Accepted: 26 December 2017
First Online: 4 January 2018
